We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
EAMS scientific opinion issued to Bristol-Myers Squibb Pharmaceuticals Limited for Nivolumab as monotherapy treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal, squamous cell carcinoma (OSCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Employment Tribunal decision.
Response provided by the Scotland Office on early release schemes for headcount reduction.
Wales Office response to Freedom of Information request ‘Early release schemes’.
Pharmaswiss Česka republika s.r.o. is initiating an urgent recall of all batches of Emerade 500 micrograms and Emerade 300 micrograms auto-injectors.
Upper Tribunal Tax and Chancery decision of Judge Thomas Scott and Judge Anne Redston on 24 August 2022
FOI 5946 We received a request under the Freedom of Information Act for the following. 1) The number of foreign national prisoners removed…
This publication sets out the Secretary of State's call to action to reduce the number of people dying prematurely.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Risk of early psychiatric side-effects is one of several important safety issues for healthcare professionals to discuss with patients and carers, who should seek urgent medical advice in the event of any worrying symptoms.
Cases of sexual dysfunction, predominantly involving erectile dysfunction and decreased libido, have been reported rarely in patients taking oral isotretinoin for severe acne.
Freedom of Information response about clarifying an early MOT test for a vehicle.
Early morning tests and MMA risk assessments.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).